Top Markets
Coin of the day
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
Rank in Stocks #5950
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Share Price
$45.79
Market Cap
$2.33B
Change (1 day)
11.43%
Change (1 year)
408.10%
Country
FR
Trade Nanobiotix S.A. (NANO)

Category

P/B ratio for Nanobiotix S.A. (NANO)
P/B ratio as of 2026 TTM: 0
According to Nanobiotix S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Nanobiotix S.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH